GU Oncology Now Journal

A publication highlighting original articles and interviews.

ASTRO 2022 Postprostatectomy Radiation Highlights
Many patients diagnosed with localized prostate cancer will undergo primary therapy with radical prostatectomy. An estimated 25% to 40% of such patients will eventually experience biochemical recurrence (BCR) by 10 years after primary therapy.1,2 Postprostatectomy patients with BCR may be offered salvage radiation therapy if they have a rising detectable prostate-specific antigen (PSA) level and no radiographic evidence of nodal or metastatic disease. At the American Society for Radiation Oncology (ASTRO) 2022 meeting, several authors presented abstracts on the topic of postprostatectomy radiation that are worth reviewing. ...
Advertisement

Articles from the Latest Issue

David Ambinder, MDJournal | December 19, 2022
Upfront cytoreductive nephrectomy for patients with MRCC with immune checkpoint inhibitors or targeted therapy is examined.
Read More
Daniel Tennenbaum, MDExpert Interviews | December 19, 2022
Dr. Daniel Tennenbaum interviews Dr. Catherine H. Marshall on trends in managing advanced and metastatic prostate cancer.
Linda Brookes, MScJournal | December 19, 2022
Dr. Yasser Ged describes his GU oncology career that has spanned over three continents.
Michael R. Page, PharmD, RPhJournal | December 19, 2022
The Uromigos: Live & Unplugged event incorporated presentations and discussions in the field of urologic malignancies.
Akhil Abraham Saji, MDJournal | December 19, 2022
A detail of the analgesic modalities available for treatment of patients undergoing minimally-invasive urologic surgery.
David Ambinder, MDJournal | December 19, 2022
According to a recent study published in The Lancet Oncology, radiation may offer safety and long-term efficacy for RCC.
Advertisement

Browse Our Past Issues

Advertisement
Advertisement
Editorial Advisory Board